EDCTP    [to 2 Jun 2018]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
1 June 2018
EDCTP launches €118 million investment
EDCTP published its 2018 calls for proposals after approval of its 2018 work plan. The eleven calls represent an overall investment of €118 million in clinical research and research capacity in sub-Saharan Africa.

29 May 2018
Invitation to Financial and Project Management Training for EDCTP2 grantees
EDCTP is inviting current and future grantees to participate in a one-day workshop on financial and project management of EDCTP2 grants. The workshop will be held in The Hague, the Netherlands, on 12 July 2018.


European Medicines Agency  [to 2 Jun 2018]
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 May 2018
Nine medicines recommended for approval, including two orphans

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 23–25 May 2018
New vaccine to reduce the incidence of intramammary infections in cows/heifers recommended for approval …
European Vaccine Initiative  [to 2 Jun 2018]
01 June 2018
TRANSVAC: European Training in Vaccinology
First call for training modules
25 May 2018
Data protection & GDPR
EVI and Processing personal data on the basis of the EU/EEA General Data Protection Regulation
FDA [to 2 Jun 2018]
May 30, 2018 –
Statement from FDA Commissioner Scott Gottlieb, M.D., on the signing of the Right to Try Act


GHIT Fund   [to 2 Jun 2018]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical ·
June 1, 2018
GHIT’s 2017 Annual Report Published
GHIT Fund Website Renewed
Together we are better, together we are GHIT [film]

May 27, 2018 | Publications
Strategic Plan 2018 Published

IVI   [to 2 Jun 2018]
Mr. George Bickerstaff elected Chair of IVI Board of Trustees, Dr. Hanna Nohynek Vice-Chair
The International Vaccine Institute (IVI) today announced that Mr. George Bickerstaff, currently Vice-Chair and Board member since 2009, has been elected as the new Chair of the Board of Trustees of the Institute and Dr. Hanna Nohynek, a Board member since 2016, has been elected as Vice-Chair of the Board. Both appointments are for three-year terms.
Mr. Bickerstaff is a leader in business and philanthropy, with over 35 years of experience in healthcare and finance. He is currently Managing Director of M.M. Dillon & Co., a private investment bank which he co-founded, and previously held the position of Chief Financial Officer of Novartis Pharma AG. He has also worked at Dun & Bradstreet and General Electric…
Dr. Nohynek, the new Vice-Chair, is currently Chief Medical Officer and Deputy Head of Infectious Diseases Control and Vaccines Unit at the National Institute for Health and Welfare in Finland. A practicing physician and vaccinologist, Dr. Nohynek has served on expert committees evaluating the introduction of pneumococcal conjugate vaccines (PCV) and rotavirus vaccine in Finland, and as a technical advisor to the European Union, IVI, the World Health Organization, Gavi, the Finnish Ministry of Foreign Affairs, and several vaccine manufacturers.
IVI Director General, Dr. Jerome Kim said, “IVI is very pleased to welcome Mr. George Bickerstaff, Chair and Dr. Hanna Nohynek, Vice-Chair, in their new appointments. I am sure they will continue to bring a wealth of expertise and experience to the leadership of the board. Under their guidance, IVI will fulfill its commitment to accelerate vaccine research and development to give vulnerable people everywhere the opportunity to lead healthy and productive lives.”

IVI Annual Report 2017

MSF/Médecins Sans Frontières  [to 2 Jun 2018]
Press release
South Africa Takes Landmark Step to Ensure More People Have Access to Lifesaving Medicines
June 01, 2018
The government of South Africa released its new intellectual property policy this week, proposing important amendments to the country’s flawed patent law which will help ensure improved access to affordable generic medicines, said the international medical humanitarian organization Doctors Without Borders/ Médecins Sans Frontières (MSF) Friday.

Press release
DRC: MSF begins Ebola vaccination trial in Bikoro to help curb outbreak
NEW YORK/KINSHASA, MAY 29, 2018—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) started vaccinating Ebola frontline workers yesterday in Bikoro, Equateur Province, Democratic Republic of Congo (DRC). The vaccination, which is being conducted with Epicentre—MSF’s research arm—will also be offered to contacts of patients. The start of the Bikoro trial comes about a week after health care workers in Mbandaka began receiving the vaccine.
[See Milestones above for more detail]
NIH  [to 2 Jun 2018]
May 30, 2018
NIH scientists show how tularemia bacteria trick cells to cause disease
— Findings could play a role in developing effective treatment strategies.


PATH  [to 2 Jun 2018]
Press release
Over 1,000 people in Vietnam have taken pre-exposure prophylaxis (PrEP) drugs to reduce the risk of HIV infection
Ho Chi Minh City, Tuesday, May 29, 2018—Today at a workshop in Ho Chi Minh City, the Vietnam Administration for HIV/AIDS Control (VAAC), the United States Agency for International Development (USAID), the World Health Organization (WHO), and PATH revealed that nearly 1,200 people at high risk of HIV have enrolled in pilot oral pre-exposure prophylaxis (PrEP) programs in Vietnam in order to reduce their risk of infection.
PrEP is a combination of two antiretroviral drugs, which, if taken daily as prescribed, can reduce the risk of HIV infection for people who are at high risk (including men who have sex with men [MSM], transgender women [TGW], and the HIV-negative partners of those diagnosed with HIV) by 92 to 99 percent. WHO has recommended the use of PrEP for people at substantial risk of HIV since 2015, as part of a combination HIV prevention strategy that includes the use of condoms…


UNAIDS [to 2 Jun 2018]
29 May 2018
A pledge to respond to falsified and substandard health products in francophone Africa
Twenty-five countries and 10 international organizations have pledged to respond to falsified and substandard medicines in French-speaking Africa.
On the sidelines of the 71st session of the World Health Assembly on 22 May, the Organisation internationale de la Francophonie (OIF) and UNAIDS, in collaboration with the World Health Organization and the Fondation Chirac, hosted a conference entitled Access to Quality Medicines and Other Medical Products in Francophone Africa, which brought together nearly 400 participants, including a number of health ministers. They adopted a declaration with commitments to advance access for all, especially the poorest, to assured-quality health products…
The signed declaration aims to foster mechanisms to assure the quality of all health products that reach the African market. Therefore, it calls for the strengthening of health regulatory capacities in the continent, paving the road for the local production of medicines.
OIF’s Secretary-General, Michaëlle Jean, would like the document to be the basis of an action plan. “We intend to raise this with all heads of state and government of the francophone area at the 17th Francophonie Summit in October, mobilizing them around concrete solutions and sustainable financing at the national, regional and international levels,” she said.
Declaration text:

28 May 2018
HIV transmission filmed live by French scientists
A team of French researchers has succeeded in filming HIV infecting a healthy cell. UNAIDS spoke to Morgane Bomsel, Research Team Director at the French National Center for Scientific Research (CNRS), about the feat.


Vaccine Education Center – Children’s Hospital of Philadelphia  [to 2 Jun 2018]
Published on May 23, 2018
Dr. Offit Addresses New Hepatitis B Vaccine for Adults
In this video, Dr. Offit talks about the vaccine technology advancements used to make the improved hepatitis B vaccines for adults. These include the advent of a new adjuvant that evokes a stronger immune response and delivers better protection:
Wellcome Trust  [to 2 Jun 2018]
News / Published: 29 May 2018
New fund to support groundbreaking open research
Our new Open Research Fund supports innovative approaches that enable data, code or other research outputs to be discovered, accessed and reused.
It will allow researchers from any discipline to do experiments at the cutting edge of open research and evaluate the benefits and risks of their approach.
The awards are:
:: for new activities or to develop existing activities
:: open to individuals or teams from anywhere in the world
:: up to £50,000 each.
We’ll be accepting applications once a year.
Robert Kiley, Head of Wellcome’s Open Research team, says: “We believe the research community are best placed to devise new and innovative ways to make research outputs more open and usable.
“These awards provide a unique opportunity for the most interesting and groundbreaking proposals to be developed, tested and evaluated.”
The Wistar Institute   [to 2 Jun 2018]
Press Release  May. 30, 2018
Wistar Receives Grant from the Jayne Koskinas Ted Giovanis Foundation for Health and Policy to Support the Breast Cancer Research Consortium
The Jayne Koskinas Ted Giovanis Foundation for Health and Policy (JKTG Foundation) awarded The Wistar Institute a $840,000 grant, over three years, to support the Jayne Koskinas Ted Giovanis Breast Cancer Research Consortium at Wistar.

World Organisation for Animal Health (OIE)   [to 2 Jun 2018]
International partnership to address human-animal-environment health risks gets a boost
Paris, 30 May 2018 – The Food and Agriculture Organization of the United Nations (FAO), the World Health Organization (WHO) and the World Organisation for Animal Health (OIE) today agreed to step up joint action to combat health threats associated with interactions between humans, animals and the environment.
In a Memorandum of Understanding signed today, FAO, OIE and WHO agreed to strengthen their long-standing partnership, with a strong focus on tackling antimicrobial resistance (AMR)…
Joint activities under the new agreement will include:
:: Supporting the Interagency Coordination Group on AMR established by the United Nations General Assembly in 2016, as well as the continuing implementation of the Global Action Plan on AMR
:: Engaging with countries to reinforce national and regional human health, animal health and food safety services
:: Improving inter-agency collaboration in foresight analysis, risk assessment, preparedness building and joint responses to emerging, remerging and neglected infectious diseases at the animal-human-ecosystems interface
:: Addressing food safety challenges requiring a multi-sector approach in the context of reinforcing food security.
:: Promoting coordinated research and development to achieve a common understanding of the highest priority zoonotic diseases and the research and development needed to prevent, detect, and control them
:: Developing a Voluntary Code of Conduct to reinforce implementation of international standards on responsible and prudent use of antimicrobials.

BIO    [to 2 Jun 2018]
access to the medicines they need …”

IFPMA   [to 2 Jun 2018]
28 May 2018
The R&D-based pharmaceutical industry supports the World Health Organization 5-year work plan and welcomes new
Geneva – IFPMA, the voice of the biopharmaceutical innovation and health progress around the world, made a series of statements during the 71st World Health Assembly. As the Assembly kicked off, IFPMA called for even greater collaboration as being critical to future global health progress. In his inaugural and closing remarks, Dr Tedros Adhanom Ghebreyesus, WHO’s Director General, highlighted the role of the private sector and the need to engage in “whatever partnerships are open to us, in whatever way we can, to achieve our goal”.

During this year’s Assembly, IFPMA celebrated its 50th anniversary and launched a report “50 Years of Global Health Progress” at the event “Continuing progress in global health: Working together for the future”. Reflecting on a productive Assembly: Thomas Cueni, IFPMA’s Director General stated: “We offer our support to WHO in this new era of global health partnerships to deliver on our shared objective for improved health outcomes and impacts. In tackling the healthcare challenges of the developing world, we need to leave our own ‘comfort zone’ and collaborate with others, be it in engaging on health systems reform or in partnerships to bring innovative medicines to millions of more people in resource constrained settings.”

IFPMA was pleased that the WHO General Program of Work (GPW) was approved. In its statement, IFPMA welcomed the ambitious goals and the focus on outcomes and impact: “We strongly agree that the private sector is a key partner to achieving its targets and we stand ready to play our part. As a non-State actor in longstanding official relations with WHO, we look forward to continuing and strengthening our history of collaboration to help WHO in catalysing the scaling up and sustainability of effective, health innovations”…